

# 2<sup>nd</sup> Annual Tennessee Oncology Pharmacists Association Meeting

September 9<sup>th</sup>, 2017  
Belmont University, Nashville, TN

Target Audience: Pharmacists

## Registration Fees:

Belmont Full Time Faculty/Student: \$20  
Early Registration (TOPA member, through August 15): \$100  
Early Registration (non-member, through August 15): \$125  
Registration (August 16-September 6): \$150  
NPs, PAs, Nurses- \$30  
Residents- \$0

## Program Agenda

- 8:15am-8:45am - Updates in Treatment of Acute Myeloid Leukemia (0.5 CEUs)  
UAN: 0863-9999-17-063-L04-P
  - o Lydia Benitez, PharmD, BCOP
    - Describe mechanism of action of novel agents in treatment of AML
    - Discuss data and place in therapy for newly approved agents
    - Review recent data regarding dosing and scheduling of standard of care regimens
  
- 8:45am-9:15am - Immunotherapy in Hematologic Malignancies (0.5 CEUs)  
UAN: 0863-9999-17-061-L04-P
  - o Katie Culos, PharmD, BCOP
    - Review the principles of immunotherapy in the treatment of hematologic malignancies
    - Discuss chimeric antigen receptor (CAR) T-cell targets and current treatment strategies integrating recent data on patterns of response and mechanisms of resistance
    - Summarize novel immunotherapy approaches in development for treatment of hematologic malignancies
    - Evaluate common toxicities of immunotherapy and highlight the pharmacists' role for ensuring safe immunotherapy treatment
  
- 9:15am-10:15am - Review of Post-Stem Cell Transplant Maintenance Therapies (1.0 CEUs)  
UAN: 0863-9999-17-053-L04-P
  - o Katie Gatwood, PharmD, BCOP
  - o Objectives
    - Discuss the rationale for use of maintenance therapy following stem cell transplantation
    - Summarize maintenance therapy strategies utilized following autologous stem cell transplantation
    - Summarize maintenance therapy strategies utilized following allogeneic stem cell transplantation
    - Identify appropriate candidates for post-transplant maintenance therapy

- 10:30am-11:30am - Multiple Myeloma Treatment at Initial Relapse (1.0 CEUs)  
UAN: 0863-9999-17-054-L04-P
  - o Justin Arnall, PharmD, BCOP
  - o Objectives
    - Review initial treatment recommendations and considerations for multiple myeloma, including roles of iMIDs and proteasome inhibitor-based therapy and hematopoietic stem cell transplantation
    - Compare recent literature on multi-agent treatment regimens for myeloma in first relapse
    - Review toxicity profile and important supportive considerations for novel agents
    - Apply novel treatment strategies to patient cases based on literature supported outcomes as well as patient-specific comorbidities
  
- 11:30am-12:00pm - Update on Ovarian Cancer and PARP Inhibitors (0.5 CEUs)  
UAN: 0863-9999-17-055-L01-P
  - o Renee McAlister, PharmD
  - o Objectives
    - Review the pathophysiology of ovarian cancer
    - Summarize current treatment recommendations for ovarian cancer
    - Explore new treatment options for recurrent ovarian cancer, with a focus on PARP inhibitors
    - Discuss future directions for treatment of ovarian cancer
  
- 1:00pm-2:00pm - New Drug Update (1.0 CEUs)  
UAN: 0863-9999-17-056-L01-P
  - o Erin Steinwedel, PharmD
  - o Objectives
    - Describe the therapeutic classifications and indications for select new oncologic agents approved in last year
    - Discuss dosing, administration, and appropriate role for each new agent
    - List major adverse effects, contraindications, and precautions for each new agent
    - Discuss special considerations in regards to storage, preparation, dispensing and monitoring each new agent
  
- 2:00pm-3:00pm - Cancer and Clots: Approaching the Use of DOACs in the Cancer Population (1.0 CEUs)  
UAN: 0863-9999-17-057-L04-P
  - o Alex Shillingburg, PharmD, BCOP
  - o Objectives
    - Recognize and discuss the 4 new oral anticoagulant (NOAC) drugs, their clinical indications, dosing, and special considerations
    - Determine patients that would be appropriate candidates for therapy with these NOACs
    - Apply currently available data to assess the utility of these medications in patients with cancer
  
- 3:00pm-3:30pm - Why You Didn't Get Paid for That Expensive Drug (0.5 CEUs)  
UAN: 0863-9999-17-066-L04-P
  - o Jody Hume Rowland
  - o Objectives
    - Clarify the navigation process for high cost drugs from order to adjudication.
    - Highlight the challenges in receiving maximum reimbursement.
    - Examples of pharmacist interaction to assist the positive outcome in drug claims.

- 3:45pm-4:15pm - How to Transition Inpatient Chemotherapy Regimens to the Ambulatory Setting (0.5 CEUs)  
UAN: 0863-9999-17-058-L04-P
  - o Dragos Plesca, PharmD, PhD, BCOP
  - o Objectives
    - Identify the advantages associated with transitioning inpatient chemotherapy regimens to the ambulatory setting and the benefits to the patient and the healthcare system
    - Recognize the potential barriers and limitations that may be encountered during this transition
    - Discuss the stepwise approach to the implementation process and how to overcome these potential barriers
  
- 4:15pm-4:45pm - Efforts Toward and Need for the Passing of Oral Parity Legislature in Tennessee (0.5 CEUs)  
UAN: 0863-9999-17-059-L03-P
  - o Glenn Roma, PharmD, PhD
  - o Objectives
    - Define oral parity laws
    - Summarize the status of oral parity legislation in the United States and in Tennessee
    - Identify the necessary steps to proceed toward passing of oral parity legislature
  
- 4:45pm-5:45pm - Telepharmacy in the Outpatient Oncology Infusion Setting (1.0 CEUs)  
UAN: 0863-9999-17-060-L04-P
  - o Alexander Quesenberry, PharmD, BCPS, BCOP and Kimberly Scroggins, PharmD
  - o Objectives
    - Define telepharmacy
    - Describe the different ways to utilize telepharmacy within your organization
    - Describe how telepharmacy can allow a pharmacist to provide oversight to a remote clinic

Thank you to our sponsors Abbvie, Amgen, Astra Zeneca, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Genentech, ICU Medical, Lilly Oncology, Jazz Pharmaceuticals, and Spectrum Pharmaceuticals.



Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These knowledge-based activities provide up to 8.00 contact hours (.80 CEUs) of continuing education credit. Continuing education statements of credit will be available to attendees who attend the live seminars and complete the online evaluation.